This led on average to a 63% increase in cell lysis rates by CD276-directed CAR NK-92 cells (Figure 2I), compared to no changes for anti-HLA-I siRNA treated HLA-Ilow cells (all cancer cells, except for LK7; Figures 2J and S6). This evidence concerns the gene CD276 and cancer.